| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts
Requests for reprints: Michael V. Seiden, Department of Hematology/Oncology, Massachusetts General Hospital, Cox 640, Boston, MA 02114. Phone: 617-724-3123; Fax: 617-724-3166. E-mail: mseiden{at}partners.org
Ovarian cancer is currently the most lethal gynecologic malignancy in developed countries, and paclitaxel is a cornerstone in the treatment of this malignancy. Unfortunately, the efficacy of paclitaxel is limited by the development of drug resistance. Clinical paclitaxel resistance is often associated with ABCB1 (MDR1) overexpression, and in vitro paclitaxel resistance typically demonstrates overexpression of the ABCB1 gene. In this study, we demonstrate that paclitaxel-resistant cell lines overexpress both ABCB1 and ABCB4 (MDR3). To evaluate the role of these transporters in paclitaxel-resistant ovarian cancer cells, small interference RNAs (siRNAs) were used to target ABCB1 and ABCB4 RNA in the paclitaxel-resistant SKOV-3TR and OVCAR8TR ovarian cancer cell lines. Treatment of these lines with either chemically synthesized siRNAs or transfection with specific vectors that express targeted siRNAs demonstrated decreased mRNA and protein levels of ABCB1 or ABCB4. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assays of siRNA-treated cells demonstrated 7- to 12.4-fold reduction of paclitaxel resistance in the lines treated with the synthesized siRNA of ABCB1 and 4.7- to 7.3-fold reduction of paclitaxel resistance in the cell lines transfected with siRNA of ABCB1 expressing vectors. ABCB4 siRNA-treated cell lines showed minor reduction in paclitaxel resistance. These results indicate that siRNA targeted to ABCB1 can sensitize paclitaxel-resistant ovarian cancer cells in vitro and suggest that siRNA treatment may represent a new approach for the treatment of ABCB1-mediated drug resistance.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Note: Presented in part at the RNAi 2003 Boston Meeting, May 5 to 6, 2003, Waltham, Massachusetts.
Received 12/17/03; revised 4/ 6/04; accepted 4/29/04.
This article has been cited by other articles:
|
|
 |
|
  Z. Duan, E. J. Weinstein, D. Ji, R. Y. Ames, E. Choy, H. Mankin, and F. J. Hornicek Lentiviral short hairpin RNA screen of genes associated with multidrug resistance identifies PRP-4 as a new regulator of chemoresistance in human ovarian cancer Mol. Cancer Ther., August 1, 2008; 7(8): 2377 - 2385. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Devalapally, Z. Duan, M. V. Seiden, and M. M. Amiji Modulation of Drug Resistance in Ovarian Adenocarcinoma by Enhancing Intracellular Ceramide Using Tamoxifen-Loaded Biodegradable Polymeric Nanoparticles Clin. Cancer Res., May 15, 2008; 14(10): 3193 - 3203. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Stierle, M. Duca, L. Halby, C. Senamaud-Beaufort, M. L. Capobianco, A. Laigle, B. Jolles, and P. B. Arimondo Targeting MDR1 Gene: Synthesis and Cellular Study of Modified Daunomycin-Triplex-Forming Oligonucleotide Conjugates Able to Inhibit Gene Expression in Resistant Cell Lines Mol. Pharmacol., May 1, 2008; 73(5): 1568 - 1577. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Oguri, H. Ozasa, T. Uemura, Y. Bessho, M. Miyazaki, K. Maeno, H. Maeda, S. Sato, and R. Ueda MRP7/ABCC10 expression is a predictive biomarker for the resistance to paclitaxel in non-small cell lung cancer Mol. Cancer Ther., May 1, 2008; 7(5): 1150 - 1155. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-Y. Katoh, M. Ueno, and N. Takakura Involvement of MDR1 Function in Proliferation of Tumour Cells J. Biochem., April 1, 2008; 143(4): 517 - 524. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Sarkadi, L. Homolya, G. Szakacs, and A. Varadi Human Multidrug Resistance ABCB and ABCG Transporters: Participation in a Chemoimmunity Defense System. Physiol Rev, October 1, 2006; 86(4): 1179 - 1236. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. P. Szotek, R. Pieretti-Vanmarcke, P. T. Masiakos, D. M. Dinulescu, D. Connolly, R. Foster, D. Dombkowski, F. Preffer, D. T. MacLaughlin, and P. K. Donahoe Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness PNAS, July 25, 2006; 103(30): 11154 - 11159. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Sparreboom and W. D. Figg Identifying sources of interindividual pharmacokinetic variability with population modeling. Clin. Cancer Res., April 1, 2006; 12(7): 1951 - 1953. [Full Text] [PDF]
|
|
|
|
|
|
M. Komatsu, K. Hiyama, K. Tanimoto, M. Yunokawa, K. Otani, M. Ohtaki, E. Hiyama, J. Kigawa, M. Ohwada, M. Suzuki, et al. Prediction of individual response to platinum/paclitaxel combination using novel marker genes in ovarian cancers. Mol. Cancer Ther., March 1, 2006; 5(3): 767 - 775. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P.L. R. Ee, X. He, D. D. Ross, and W. T. Beck Modulation of breast cancer resistance protein (BCRP/ABCG2) gene expression using RNA interference Mol. Cancer Ther., December 1, 2004; 3(12): 1577 - 1584. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
